Penumbra, Inc.: How Is It Expanding into International Markets, Dealing With Competitive Dynamics & Executing Market Share Expansion?

The second quarter 2024 financial results for Penumbra, Inc. reveal a combination of strengths and challenges that frame the investment outlook for the company. In Q2 2024, Penumbra reported revenues of $299.4 million, reflecting a 14.5% increase year-over-year, driven particularly by robust performance in the U.S. thrombectomy market, which saw a growth of 25% compared to the same period in the previous year. This growth was predominantly fueled by strong demand for the company’s CAVT products in both venous thromboembolism (VTE) and arterial sectors.